Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185196 | 0.92 | KDM4E (0.57) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL14185215 | 0.88 | MAPT (0.48) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL2184783 | 0.85 | KDM4E (0.62) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL2333853 | 0.85 | ALDH1A1 (0.48) | MAPTKDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL14185253 | 0.83 | CA1 (0.52) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL3589703 | 0.81 | CA12 (0.54) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL3577904 | 0.79 | CA1 (0.52) | CA1CA2KDM4EALDH1A1GAA | |
| SCHEMBL3578968 | 0.79 | CA1 (0.50) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL14185257 | 0.78 | SMN1; SMN2 (0.51) | CA1CA2MAPTKDM4EALDH1A1 | |
| SCHEMBL3579502 | 0.78 | CA1 (0.58) | CA1CA2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | TRPV1, CHRM3, TRPV3 | CA1 1347/4885CA2 224/4885MAPT 4741/4885 |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | CA1 2466/4885CA2 628/4885MAPT 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.